BioCorRx Reports Business Update for the Second Quarter of 2024
BioCorRx Inc. (OTCQB: BICX), a developer of innovative substance abuse treatment programs, provided a business update for Q2 2024. Key highlights include:
1. Expansion of intellectual property portfolio with a new international patent from Israel for weight loss treatment using naltrexone implants.
2. A new USPTO patent for a novel compound potentially reducing opioid withdrawal symptoms.
3. A $11 million grant from NIDA for developing BICX104, a long-duration naltrexone implant for methamphetamine use disorder (MUD).
The company remains focused on addressing global unmet medical needs in obesity and substance abuse, with ongoing progress in development efforts and strategic priorities aimed at creating shareholder value.
BioCorRx Inc. (OTCQB: BICX), un sviluppatore di programmi innovativi per il trattamento delle dipendenze, ha fornito un aggiornamento aziendale per il secondo trimestre del 2024. I principali aspetti salienti includono:
1. Espansione del portafoglio di proprietà intellettuale con un nuovo brevetto internazionale da Israele per il trattamento della perdita di peso utilizzando impianti di naltrexone.
2. Un nuovo brevetto USPTO per un composto innovativo che potrebbe ridurre i sintomi di astinenza da oppiacei.
3. Un finanziamento di 11 milioni di dollari da NIDA per lo sviluppo di BICX104, un impianto di naltrexone a lunga durata per il disturbo da uso di metanfetamina (MUD).
La società rimane concentrata nell'affrontare le esigenze mediche globali non soddisfatte in materia di obesità e dipendenze, con progressi continui negli sforzi di sviluppo e nelle priorità strategiche volte a creare valore per gli azionisti.
BioCorRx Inc. (OTCQB: BICX), un desarrollador de programas innovadores para el tratamiento de adicciones, proporcionó una actualización empresarial para el segundo trimestre de 2024. Los puntos destacados incluyen:
1. Expansión de la cartera de propiedad intelectual con una nueva patente internacional de Israel para tratamiento de pérdida de peso utilizando implantes de naltrexona.
2. Una nueva patente USPTO para un compuesto novedoso que podría reducir los síntomas de abstinencia de opioides.
3. Una subvención de 11 millones de dólares de NIDA para el desarrollo de BICX104, un implante de naltrexona de larga duración para el trastorno por uso de metanfetaminas (MUD).
La empresa sigue enfocada en abordar las necesidades médicas no satisfechas en todo el mundo en obesidad y abuso de sustancias, con progresos en curso en los esfuerzos de desarrollo y prioridades estratégicas destinadas a crear valor para los accionistas.
BioCorRx Inc. (OTCQB: BICX)는 혁신적인 약물 남용 치료 프로그램 개발 회사로서 2024년 2분기 비즈니스 업데이트를 제공했습니다. 주요 사항은 다음과 같습니다:
1. 이스라엘에서의 국제 특허 획득으로 체중 감소 치료를 위한 지적 재산 포트폴리오 확대.
2. 오피오이드 금단 증상을 줄일 수 있는 새로운 화합물에 대한 USPTO 신규 특허.
3. 메스암페타민 사용 장애(MUD)를 위한 장시간 지속 가능한 naltrexone 임플란트 BICX104 개발을 위한 NIDA의 1,100만 달러 지원.
회사는 비만 및 약물 남용 분야의 전 세계적인 미충족 의료 요구를 해결하는 데 집중하고 있으며, 지속적인 개발 노력과 주주 가치를 창출하기 위한 전략적 우선 사항을 추진하고 있습니다.
BioCorRx Inc. (OTCQB: BICX), un développeur de programmes innovants de traitement des abus de substances, a fourni une mise à jour commerciale pour le deuxième trimestre de 2024. Les faits marquants comprennent :
1. Expansion du portefeuille de propriété intellectuelle avec un nouveau brevet international d'Israël pour le traitement de la perte de poids utilisant des implants de naltrexone.
2. Un nouveau brevet USPTO pour un composé novateur visant à réduire les symptômes de sevrage aux opioïdes.
3. Une subvention de 11 millions de dollars de la NIDA pour le développement de BICX104, un implant de naltrexone à longue durée d'action pour le trouble lié à l'utilisation de méthamphétamine (MUD).
L'entreprise reste concentrée sur la résolution des besoins médicaux non satisfaits dans le monde en matière d'obésité et d'abus de substances, avec des progrès continus dans ses efforts de développement et ses priorités stratégiques visant à créer de la valeur pour les actionnaires.
BioCorRx Inc. (OTCQB: BICX), ein Entwickler innovativer Programme zur Behandlung von Substanzmissbrauch, hat ein Unternehmensupdate für das zweite Quartal 2024 bereitgestellt. Zu den wichtigsten Punkten gehören:
1. Erweiterung des Portfolios an geistigem Eigentum mit einem neuen internationalen Patent aus Israel zur Gewichtsreduktion mittels Naltrexon-Implantaten.
2. Ein neues USPTO-Patent für eine neuartige Verbindung, die möglicherweise Entzugssymptome bei Opioiden reduzieren kann.
3. Ein Fördermittel von 11 Millionen Dollar von NIDA zur Entwicklung von BICX104, einem Langzeit-Naltrexon-Implantat zur Behandlung von Methamphetamin-Abhängigkeit (MUD).
Das Unternehmen bleibt darauf fokussiert, unbefriedigte medizinische Bedürfnisse in den Bereichen Fettleibigkeit und Substanzmissbrauch weltweit zu adressieren und erzielt fortlaufende Fortschritte in seinen Entwicklungsanstrengungen und strategischen Prioritäten mit dem Ziel, den Aktionärswert zu erhöhen.
- Awarded new international patent from Israel for weight loss treatment
- Granted new USPTO patent for novel compound potentially reducing opioid withdrawal symptoms
- Received $11 million grant from NIDA for BICX104 development
- Expanding intellectual property portfolio in obesity and substance abuse treatment
- None.
ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments.
Additionally, BioCorRx Inc. announces the expansion of its intellectual property portfolio with a new international patent awarded from Israel for the treatment of weight loss. This patent covers the use of a subcutaneous implant containing naltrexone to aid in weight loss when combined with behavioral and/or nutritional counseling and therapy. This patent aligns with BioCorRx’s long-term goals of addressing the global unmet medical needs related to obesity and strengthens the Company’s IP portfolio.
Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In the second quarter of 2024, we announced that our subsidiary, BioCorRx Pharmaceuticals Inc., was granted a new patent by the United States Patent and Trademark Office (USPTO) for a novel compound. We believe this patented invention could offer a new approach to reducing the severity of withdrawal symptoms for opioid use disorder (OUD) compared to current treatments. Recently, we were granted a new patent from Israel for the use of a subcutaneous naltrexone implant to aid weight loss when combined with behavioral or nutritional counseling. This further expands our IP portfolio and supports our goals in addressing global obesity.”
“Additionally in February 2024, BioCorRx Pharmaceuticals received a 3-year grant totaling approximately
A copy of the Company’s quarterly report on Form 10-Q for the second quarter ended June 30, 2024, has been filed with the Securities and Exchange Commission and posted on the Company’s website at https://ir.biocorrx.com/.
About BICX104
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of Opioid Use Disorder “OUD” being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed treatments. In Phase I, an open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the PK and safety of BICX104 and the once-a-month intramuscular naltrexone injection (Vivitrol), BICX104 was well tolerated with no serious adverse events and achieved 84 days of therapeutic naltrexone plasma concentrations. BICX104 is being developed under BioCorRx Pharmaceuticals Inc., the Company’s majority-owned clinical-stage pharmaceutical subsidiary.
Information about the study can also be found at www.clinicaltrials.gov under NCT number 04828694.
BICX104 is being developed through a cooperative agreement with the NIDA, part of the NIH, under award number UH3DA047925, funded by the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. This award is subject to the Cooperative Agreement Terms and Conditions of Award as set forth in RFA DA-19-002 entitled, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional).
The NIH Helping to End Addiction Long-term® Initiative or NIH HEAL Initiative®, is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction and enhancing pain management. For more information, visit: https://heal.nih.gov.
Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number U01DA059994 and UH3DA047925. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About MUD
Research has shown that methamphetamine is a highly addictive stimulant and one of the most misused stimulant drugs in the world. Some of the side effects of MUD are severe dental problems, memory loss, aggression, psychotic behavior, and damage to the cardiovascular system. In 2022 the National Survey on Drug Use and Health reported that more than 16.6 million people used methamphetamine at least once during their lifetime.
About OUD
OUD is a chronic disorder, with serious potential consequences including disability, relapses, and death. Opioids, used medically for pain relief, have analgesic and central nervous system depressant effects as well as the potential to cause euphoria with an overpowering desire to use opioids despite the consequences. OUD can involve misuse of prescribed opioid medications, use of diverted opioid medications or illicitly obtained heroin. OUD is typically a chronic and relapsing illness that is associated with significantly increased rates of morbidity and mortality.
About Obesity
It is estimated that 1 billion people worldwide are obese. In 2024 the World Health Organization reported that one in eight people live with obesity and stressed the importance and need to curb the obesity epidemic with new interventions. It is estimated that by 2035 the global obesity crisis could rise to over 4 billion people. Affecting healthcare costs upwards of
About BioCorRx Inc.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts, and personal support from behavioral experts, please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
212- 671-1020 x304
bicx@crescendo-ir.com
FAQ
What new patent did BioCorRx (BICX) receive in Q2 2024?
What is the purpose of the $11 million grant BioCorRx (BICX) received from NIDA?
What new international patent did BioCorRx (BICX) receive for weight loss treatment?
What is BioCorRx's (BICX) main focus according to their Q2 2024 business update?
